Intravacc and Versatope sign research service agreement to develop universal influenza vaccine based on OMV technology
Intravacc and Versatope sign research service agreement to develop universal influenza vaccine based on OMV technology Bilthoven, The Netherlands, Lowell, Mass., USA, June 8 2020 – Intravacc, one of the leading translational research and development vaccine institutes with an extensive track record in developing viral and bacterial vaccines and Versatope, a U.S. biotechnology company developing…
